<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269954</url>
  </required_header>
  <id_info>
    <org_study_id>CVST2020</org_study_id>
    <nct_id>NCT04269954</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis</brief_title>
  <official_title>The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our previous clinical case observations showed that batroxobin combined with anticoagulation
      therapy can improve the sinus recanalization rate in patients with CVST, shorten the hospital
      stay, and increase the neurological score of patients. Its main mechanism is to inhibit
      thrombosis after reducing fibrinogen, and to dissolve thrombus.

      To further explore the safety of batroxobin combined with anticoagulation therapy for CVST,
      an open-label, randomized controlled (1: 1), single-center, prospective study was used.
      Further study on the safety and effectiveness of batroxobin combined with anticoagulation for
      CVST.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period</measure>
    <time_frame>2 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Favorable clinical outcome</measure>
    <time_frame>3 months after randomization</time_frame>
    <description>modified Rankin score 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalization rate of cerebral venous system</measure>
    <time_frame>3 months after randomization</time_frame>
    <description>DSA or MRV confirms cerebral venous sinus flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Required surgical intervention in relation to CVST</measure>
    <time_frame>3 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>3 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cerebral Venous Sinus Thrombosis</condition>
  <condition>Batroxobin</condition>
  <arm_group>
    <arm_group_label>Batroxobin combined with low molecular weight heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment of Batroxobin combined with low molecular weight heparin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-molecular-weight heparin therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low-molecular-weight heparin combined with routine drug therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Batroxobin combined with low molecular weight heparin</intervention_name>
    <description>Standard treatment of Batroxobin combined with low molecular weight heparin</description>
    <arm_group_label>Batroxobin combined with low molecular weight heparin</arm_group_label>
    <arm_group_label>Low-molecular-weight heparin therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cerebral venous thrombosis, confirmed by cerebral angiography (with intra-arterial
             contrast injection), magnetic resonance venography or computed tomographic venography.

          2. Severe form of CVST with a high chance of incomplete recovery, as defined by the
             presence of one or more of the following risk factors

               1. Intracerebral hemorrhagic lesion due to CVST

               2. Mental status disorder

               3. Coma (Glasgow coma scale &lt; 9)

               4. Thrombosis of the deep cerebral venous system

          3. Uncertainty by the treating physician if ET or standard heparin therapy is the optimal
             therapy for the patient.

        Exclusion Criteria:

          1. Conditions associated with increased risk of bleeding

          2. Any thrombolytic therapy within last 7 days

          3. Cerebellar venous thrombosis with 4th ventricle compression and hydrocephalus, which
             requires surgery

          4. Contraindication for anti-coagulant or batroxobin treatment 1)documented generalized
             bleeding disorder 2)concurrent thrombocytopenia (&lt;100 x 10E9/L) 3)Fibrinogen below
             100mg /dl 4)documented severe hepatic or renal dysfunction, that interferes with
             normal coagulation 5)uncontrolled severe hypertension (diastolic &gt; 120 mm Hg) 6)known
             recent (&lt; 3 months) gastrointestinal tract hemorrhage (not including hemorrhage from
             rectal hemorrhoids)

          5. Any known associated condition (such as terminal cancer) with a poor short term (1
             year) prognosis independent of CVST

          6. Clinical and radiological signs of impending transtentorial herniation due to large
             space-occupying lesions (e.g. large cerebral venous infarcts or hemorrhages)

          7. Recent (&lt; 2 weeks) major surgical procedure (does not include lumbar puncture) or
             severe cranial trauma

          8. Previously legally incompetent prior to CVST

          9. Severe renal impairment

         10. Active liver disease

         11. Pregnancy, nursing or planning to become pregnant while in the trial

         12. Further exclusion criteria apply

         13. No informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ran Meng, Ph.D</last_name>
    <phone>+86-10-83199280</phone>
    <phone_ext>+861083199280</phone_ext>
    <email>ranmeng2011@pku.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiying Chen, M.S.</last_name>
    <phone>+86-10-83199280</phone>
    <phone_ext>+861083199280</phone_ext>
    <email>chenzhiying@ccmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xuanwu Hospital, Captial Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ran Meng, Ph.D</last_name>
      <phone>+86-10-83199280</phone>
      <email>ranmeng2011@pku.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zhiying Chen, M.S.</last_name>
      <phone>+86-10-83199280</phone>
      <email>chenzhiying@ccmu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Zhiying Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiayue Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Da Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaobo Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingyuan Ya</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kexin Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhongao Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingwei Guan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jingkun Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siying Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ding J, Zhou D, Hu Y, Elmadhoun O, Pan L, Ya J, Geng T, Wang Z, Ding Y, Ji X, Meng R. The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis. J Thromb Thrombolysis. 2018 Oct;46(3):371-378. doi: 10.1007/s11239-018-1718-y.</citation>
    <PMID>30062617</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding JY, Pan LQ, Hu YY, Rajah GB, Zhou D, Bai CB, Ya JY, Wang ZA, Jin KX, Guan JW, Ding YC, Ji XM, Meng R. Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience. CNS Neurosci Ther. 2019 May;25(5):638-646. doi: 10.1111/cns.13093. Epub 2019 Jan 23.</citation>
    <PMID>30675757</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang Q, Duan J, Fan Z, Qu X, Xie Y, Nguyen C, Du X, Bi X, Li K, Ji X, Li D. Early Detection and Quantification of Cerebral Venous Thrombosis by Magnetic Resonance Black-Blood Thrombus Imaging. Stroke. 2016 Feb;47(2):404-9. doi: 10.1161/STROKEAHA.115.011369. Epub 2015 Dec 15. Erratum in: Stroke. 2016 Feb;47(2):e39.</citation>
    <PMID>26670082</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ran Meng</investigator_full_name>
    <investigator_title>Professor of neurology</investigator_title>
  </responsible_party>
  <keyword>Cerebral Venous Sinus Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinus Thrombosis, Intracranial</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Batroxobin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

